Cargando…
Anticancer effects of dihydromyricetin on the proliferation, migration, apoptosis and in vivo tumorigenicity of human hepatocellular carcinoma Hep3B cells
BACKGROUND: Hepatocellular carcinoma (HCC) represents a serious public health problem worldwide and has high morbidity and mortality. Dihydromyricetin (DHM) exhibits anticancer effect on a variety of malignancies, but its anticancer function of DHM in HCC has been unclear. The aim of this study was...
Autores principales: | Jiang, Lianggui, Ye, Wen-Chu, Li, Zuobiao, Yang, Yongguang, Dai, Wei, Li, Mingyi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8258952/ https://www.ncbi.nlm.nih.gov/pubmed/34229692 http://dx.doi.org/10.1186/s12906-021-03356-5 |
Ejemplares similares
-
Dihydromyricetin induces apoptosis and inhibits proliferation in hepatocellular carcinoma cells
por: LIU, JIE, et al.
Publicado: (2014) -
Dihydromyricetin Enhances the Chemo-Sensitivity of Nedaplatin via Regulation of the p53/Bcl-2 Pathway in Hepatocellular Carcinoma Cells
por: Jiang, Lianggui, et al.
Publicado: (2015) -
Dihydromyricetin Reduced Bcl-2 Expression via p53 in Human Hepatoma HepG2 Cells
por: Wu, Shixing, et al.
Publicado: (2013) -
Dihydromyricetin prevents cardiotoxicity and enhances anticancer activity induced by adriamycin
por: Zhu, Hong, et al.
Publicado: (2014) -
Dihydromyricetin-mediated inhibition of the Notch1 pathway induces apoptosis in QGY7701 and HepG2 hepatoma cells
por: Lu, Cai-Jie, et al.
Publicado: (2017)